4,5-Dihydroisoxazole Derivative of Ticagrelor

Estimation Of Ticagrelor In Commercial Dosage Form Using A Sensitive Validated RP-​HPLC Method
By Madhuri, K.; Rao, Y. Srinivasa; Varaprasada, Rao K.; Deepthi, R.
From World Journal of Pharmaceutical Research (2021), 10(6), 1281-1292.
 
Development and validation of stability indicating RP-​HPLC method for the estimation of Ticagrelor by forced degradation studies
By Dole, Manjusha; Kendre, Meenakshi; Wagh, Viplav
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(5), 711-724
 
Development of a validated HPLC-​PDA method for stability indicating study of ticagrelor: a novel anti-​platelet agent (P2Y12-​ADP receptor blocker)
By Sulthana, Shabana; Anuradha, V.; Rao, Mandava V. Basaveswara
From International Journal of Pharmaceutical, Chemical and Biological Sciences (2017), 7(1), 36-42
 

4,5-Dihydroisoxazole Derivative of Ticagrelor is chemically (1S,2S,3R,5S)-3-(7-((3-(3,4-difluorophenyl)-4,5-dihydroisoxazol-5-yl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. 4,5-Dihydroisoxazole Derivative of Ticagrelor is supplied with detailed characterization data compliant with regulatory guideline. 4,5-Dihydroisoxazole Derivative of Ticagrelor can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ticagrelor.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.